| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | ENG; END; HHT1; ORW1 |
| Entrez GeneID | 2022 |
| clone | 4B2A1 |
| WB Predicted band size | 70.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD105 (AA: extra 342-586) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于CD105(Endoglin)抗体的代表性文献摘要，供参考：
---
1. **文献名称**：*Targeting Endoglin (CD105) for Cancer Imaging and Therapy*
**作者**：Fonsatti E. et al.
**摘要**：综述了CD105在肿瘤血管生成中的关键作用，提出CD105抗体可用于靶向肿瘤血管的分子成像(如PET/CT)及抗体药物偶联物(ADC)治疗，并讨论其临床前研究进展。
---
2. **文献名称**：*CD105 is a marker of tumour vasculature and a potential therapeutic target*
**作者**：Duff S.E. et al.
**摘要**：通过免疫组化证实CD105在多种实体瘤(如乳腺癌、结肠癌)的新生血管中高表达，且与患者预后不良相关，提示抗CD105抗体可作为抑制肿瘤血管生成的潜在治疗策略。
---
3. **文献名称**：*Endoglin (CD105): A target for anti-angiogenetic cancer therapy*
**作者**：Rosen L.S. et al.
**摘要**：评估了抗CD105单克隆抗体(如TRC105)在临床试验中的效果，显示其通过阻断TGF-β信号通路抑制肿瘤血管生成，并在肾细胞癌和肝癌中表现出初步抗肿瘤活性。
---
如需具体引用格式或更多文献，建议通过PubMed或Web of Science以“CD105 antibody”或“Endoglin therapy”为关键词检索近年研究。
CD105. also known as endoglin, is a transmembrane glycoprotein that functions as a co-receptor in the transforming growth factor-beta (TGF-β) signaling pathway. Primarily expressed on vascular endothelial cells, it plays a critical role in angiogenesis, vascular remodeling, and maintaining vascular integrity. CD105 is a homodimeric protein with a large extracellular domain, a single transmembrane region, and a short cytoplasmic tail. Its interaction with TGF-β ligands (e.g., TGF-β1 and TGF-β3) modulates cellular responses, including proliferation, migration, and differentiation.
CD105 antibodies are widely used in research and diagnostics to identify and quantify activated endothelial cells, particularly in pathological angiogenesis associated with cancer, cardiovascular diseases, and inflammatory conditions. Unlike pan-endothelial markers (e.g., CD31), CD105 is preferentially upregulated in proliferating endothelial cells, making it a specific marker for neovascularization. In oncology, CD105 expression correlates with tumor progression, metastasis, and poor prognosis, driving its use as a therapeutic target in anti-angiogenic therapies.
Monoclonal antibodies targeting CD105. such as TRC105 (carotuximab), have been explored in clinical trials for cancers and fibrotic disorders. Additionally, CD105 antibodies are employed in techniques like immunohistochemistry, flow cytometry, and molecular imaging to assess microvessel density in tumors. Mutations in the CD105 gene are linked to hereditary hemorrhagic telangiectasia (HHT), a vascular dysplasia disorder, underscoring its physiological relevance. Overall, CD105 antibodies serve as vital tools for studying vascular biology and developing targeted therapies.
×
